Fresenius Medical Care AG

NYSE:FMS Voorraadrapport

Marktkapitalisatie: US$12.5b

Fresenius Medical Care Beheer

Beheer criteriumcontroles 1/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Helen Giza

Algemeen directeur

€5.5m

Totale compensatie

Percentage CEO-salaris30.1%
Dienstverband CEO5yrs
Eigendom CEO0.005%
Management gemiddelde ambtstermijn2yrs
Gemiddelde ambtstermijn bestuurless than a year

Recente managementupdates

Recent updates

Fresenius Medical Care: Let's Look At The Upside

Oct 04

Fresenius Medical Care: Significant Upside Remains

Jun 25

Broyhill - Fresenius Medical Care: Correctly Focused On Increasing Margins And Returns

Feb 23

Fresenius Medical Care: Don't Let The Ozempic Kidney Failure Scare You Off

Oct 12

Fresenius Medical Care: Other Stocks Still Better, But Upside Exists

Jun 01

Fresenius Medical Care Q4 2022 Earnings Preview

Feb 21

Fresenius: The Company Is Climbing, And I'm At 'Buy'

Jan 06

Fresenius: A Contrarian Opportunity Not Seen For 20 Years (Technical Analysis)

Oct 27

Fresenius Medical gains after report of activist Elliott stake in Fresenius SE

Oct 19

Fresenius cut to Hold at Jefferies citing staffing issues and inflation

Oct 10

Fresenius gets award to provide dialysis services to U.S. military veterans

Aug 30

Fresenius appoints head of pharma unit as new CEO

Aug 19

Fresenius Medical Care: Best Time In 21 Years To Buy This High-Yield Dividend Aristocrat

Jul 30

Fresenius Medical Care accused of Medicare fraud in dialysis

Jul 13

Fresenius: The Upside Is Getting Bigger

May 02

You Really Want To Know About Fresenius Medical Care

Aug 28

Fresenius Medical drops 12% on disappointing 2021 outlook

Feb 02

Fresenius Medical Care EPS beats by €0.06, misses on revenue

Oct 29

Analyse CEO-vergoeding

Hoe is Helen Giza's beloning veranderd ten opzichte van Fresenius Medical Care's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

€659m

Jun 30 2024n/an/a

€530m

Mar 31 2024n/an/a

€484m

Dec 31 2023€6m€2m

€499m

Sep 30 2023n/an/a

€450m

Jun 30 2023n/an/a

€596m

Mar 31 2023n/an/a

€602m

Dec 31 2022€3m€1m

€673m

Sep 30 2022n/an/a

€763m

Jun 30 2022n/an/a

€806m

Mar 31 2022n/an/a

€878m

Dec 31 2021€2m€855k

€969m

Sep 30 2021n/an/a

€918m

Jun 30 2021n/an/a

€998m

Mar 31 2021n/an/a

€1b

Dec 31 2020€2m€855k

€1b

Sep 30 2020n/an/a

€1b

Jun 30 2020n/an/a

€1b

Mar 31 2020n/an/a

€1b

Dec 31 2019€2m€108k

€1b

Compensatie versus markt: De totale vergoeding ($USD 5.87M ) Helen } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).

Compensatie versus inkomsten: De vergoeding van Helen is het afgelopen jaar met meer dan 20% gestegen.

CEO

Helen Giza (56 yo)

5yrs

Tenure

€5,528,000

Compensatie

Ms. Helen Giza is Chief Executive Officer and Chair of the Management Board of Fresenius Medical Care Management AG, General Partner of Fresenius Medical Care AG & Co. KGAA from December 6, 2022. She serve...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Helen Giza
Chair of Management Board & CEO5yrs€5.53m0.0047%
$ 584.4k
Martin Fischer
CFO & Member of the Management Board1.1yrs€887.00kgeen gegevens
Franklin Maddux
Global Chief Medical Officer & Member of Management Board4.8yrs€3.13m0.0062%
$ 771.7k
Katarzyna Mazur-Hofsab
CEO of Care Enablement & Member of Management Board2.8yrs€3.71m0.0039%
$ 483.2k
Craig Cordola
CEO of Care Delivery & Member of Management Boardless than a yeargeen gegevensgeen gegevens
Dominik Heger
Executive VP and Head of Investor Relationsno datageen gegevensgeen gegevens
Jorg Haring
Global Head of Legalless than a yeargeen gegevensgeen gegevens
Joachim Weith
Senior Vice President of Corporate Communications & Governmental Affairsno datageen gegevensgeen gegevens
Gail-Suzanne Brown
Senior Vice President of Research & Developmentno datageen gegevensgeen gegevens
Glenn Slater
Senior Vice President of Manufacturing and Supply Chain Operationsno datageen gegevensgeen gegevens
Wolfgang Kummerle
Senior Vice President - Quality Management Internationalno datageen gegevensgeen gegevens
Thomos Dimt
Executive Vice President of Western Europe & Nephrocare Coordination EMEALAno datageen gegevensgeen gegevens

2.0yrs

Gemiddelde duur

56.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van FMS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2 jaar), wat duidt op een nieuw team.

Bestuursleden

NaamPositieTenureCompensatieEigendom
Shervin Korangy
Independent Member of Supervisory Boardless than a year€20.00kgeen gegevens
Michael Sen
Chairman of the Supervisory Board1.3yrs€444.00kgeen gegevens
Marcus Kuhnert
Independent Member of Supervisory Boardless than a year€21.00kgeen gegevens
A. Sorensen
Independent Member of Supervisory Board3.5yrs€151.00kgeen gegevens
Stefanie Balling
Employee Representative Deputy Chairwoman of the Supervisory Boardless than a yeargeen gegevensgeen gegevens
Sara Hennicken
Member of Supervisory Boardless than a year€158.00kgeen gegevens
Frank Prescher
Employee Representative Member of Supervisory Boardless than a yeargeen gegevensgeen gegevens
Regina Karsch
Employee Representative Member of the Supervisory Boardless than a yeargeen gegevensgeen gegevens
Manuela Grabo
Employee Representative Member of the Supervisory Boardless than a yeargeen gegevensgeen gegevens
Ralf Erkens
Employee representatives Member of the Supervisory Boardless than a yeargeen gegevensgeen gegevens
Beate Habdenteufel
Employee representatives Member of the Supervisory Boardless than a yeargeen gegevensgeen gegevens

0.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FMS wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw bestuur.